Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Zyprexa · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Olanzapine Tablets 5 mg |
| 2 | ACTIVE_COMPARATOR | Zyprexa® Tablets 5 mg |
| Name | Type | Description |
|---|---|---|
| Olanzapine Tablets 5 mg | DRUG | 5mg, single dose fed |
| Zyprexa® Tablets 5 mg | DRUG | 5mg, single dose fed |
Inclusion Criteria: 1\. Age: 18 years and older. 2. Sex: Male and non-pregnant, non-lactating female 1. Women of childbearing potential must have negative serum (Beta HCG) pregnancy tests performed within 14 days prior to the start of the study and on the evening prior to each dose administration....
Zyprexa is a small molecule medicine developed by Viatris Inc. (ticker VTRS). It is also known as Zyprexa Tablets 5 mg. The clinical trial program registered for this asset consists of two completed Phase 1 studies conducted in the United States, with a combined enrollment of 62 healthy adult volunteers.
Zyprexa is developed by Viatris Inc., which trades under the ticker VTRS. The company is the sponsor associated with the registered clinical trials of Zyprexa Tablets 5 mg, including the fasting and food-effect Phase 1 studies conducted in the United States.
Zyprexa is in Phase 1 clinical development. Two Phase 1 trials are registered, both listed as completed, with no active trials currently recorded. The studies were randomized and used an active control design, and they enrolled a total of 62 participants.
Two completed Phase 1 trials are registered for Zyprexa. NCT00648921 is a fasting study of olanzapine tablets 5 mg and Zyprexa Tablets 5 mg, enrolling 30 participants. NCT00647777 is a food study of the same products, enrolling 32 participants. Both were conducted in the United States in healthy volunteers aged 18 years and older.